The presence of intratumoral SIRPα-deficient macrophages alone appears to subvert the paradigmatic immunosuppressive response to RT and instead empower IR to eliminate otherwise treatment-resistant, late-stage colorectal, and pancreatic cancers, achieving up to 100% survival rates and long-lasting humoral and cellular immunity that effectively prevent a recurrence. Here, SIRPA is linked to pancreatic neoplasm.